IL204690A0 - Azacytidine analogues and uses thereof - Google Patents

Azacytidine analogues and uses thereof

Info

Publication number
IL204690A0
IL204690A0 IL204690A IL20469010A IL204690A0 IL 204690 A0 IL204690 A0 IL 204690A0 IL 204690 A IL204690 A IL 204690A IL 20469010 A IL20469010 A IL 20469010A IL 204690 A0 IL204690 A0 IL 204690A0
Authority
IL
Israel
Prior art keywords
azacytidine
analogues
azacytidine analogues
Prior art date
Application number
IL204690A
Other languages
English (en)
Original Assignee
Clavis Pharma Asa
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clavis Pharma Asa, Sinai School Medicine filed Critical Clavis Pharma Asa
Publication of IL204690A0 publication Critical patent/IL204690A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL204690A 2007-09-26 2010-03-23 Azacytidine analogues and uses thereof IL204690A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
PCT/US2008/077673 WO2009042767A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (1)

Publication Number Publication Date
IL204690A0 true IL204690A0 (en) 2010-11-30

Family

ID=40511851

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204690A IL204690A0 (en) 2007-09-26 2010-03-23 Azacytidine analogues and uses thereof

Country Status (15)

Country Link
US (2) US8158605B2 (enExample)
EP (2) EP2197274A4 (enExample)
JP (2) JP2010540555A (enExample)
KR (2) KR20100102092A (enExample)
CN (2) CN101815437A (enExample)
AU (2) AU2008304381A1 (enExample)
BR (2) BRPI0817269A2 (enExample)
CA (2) CA2700267A1 (enExample)
IL (1) IL204690A0 (enExample)
MX (2) MX2010003002A (enExample)
NZ (2) NZ583923A (enExample)
RU (1) RU2488591C2 (enExample)
UA (2) UA99836C2 (enExample)
WO (2) WO2009042766A1 (enExample)
ZA (1) ZA201001660B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
UA99836C2 (en) * 2007-09-26 2012-10-10 Маунт Синай Скул Оф Медсин Azacytidine analogue and using thereof
ES2893785T3 (es) 2008-05-15 2022-02-10 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
EP2321302B1 (en) * 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
TW201303295A (zh) * 2011-04-15 2013-01-16 Clavis Pharma Asa 偵測血液失調中之人平衡型核苷轉運蛋白１（ｈＥＮＴ１）表現用之系統和方法
PH12014500965A1 (en) 2011-11-01 2014-06-30 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs
KR102064626B1 (ko) 2012-02-24 2020-01-09 시그날 파마소티칼 엘엘씨 Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
MX374749B (es) * 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
IL296496B2 (en) * 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
EP3383406B1 (en) 2015-12-03 2021-10-20 Epidestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
FI3600419T3 (fi) 2017-03-20 2023-11-08 Vaccinex Inc Syövän hoitaminen semaforiini-4d-vasta-aineella yhdistelmänä epigeneettistä järjestelmää moduloivan aineen kanssa
KR102795129B1 (ko) 2017-06-22 2025-04-15 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
US20230416294A1 (en) * 2020-08-10 2023-12-28 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (enExample) 1963-12-22
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3737456A1 (de) 1986-11-04 1988-05-19 Fuji Photo Film Co Ltd Laserlichtquelle
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
KR950012911B1 (ko) * 1991-02-19 1995-10-23 후지쓰 가부시끼가이샤 산소가 보강된 격리 영역이 있는 반도체와 그 제조방법
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
PL171280B1 (pl) 1991-08-14 1997-03-28 Procter & Gamble Pharma Sposób wytwarzania nowych cyklicznych uretanów PL PL
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
GB9515279D0 (en) * 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
CN1198775A (zh) 1995-08-08 1998-11-11 托马斯杰弗逊大学 重组c－蛋白酶及其加工、方法和用途
WO1997009878A1 (en) 1995-09-15 1997-03-20 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2255615C (en) 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
NZ336676A (en) 1997-01-24 2000-01-28 Norsk Hydro As Gemcitabine esters or amides useful as anti-cancer and anti-viral agents
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
CN1195769C (zh) * 1997-06-03 2005-04-06 森庸厚 天然抗肿瘤性或抗病毒性物质及其用途
AU1412299A (en) 1997-11-25 1999-06-15 Protarga, Inc. Nucleoside analog compositions and uses thereof
WO1999041231A1 (en) 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
AU5073100A (en) 1999-06-09 2001-01-02 Bayer Aktiengesellschaft Pyridine carboxamides and their use as plant protection agents
WO2001018013A1 (en) 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
RU2259360C2 (ru) 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Производные бензодиазепина и лекарственное средство, их содержащее
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
MXPA04004712A (es) 2001-11-21 2005-06-20 Heidelberg Pharma Gmbh Derivados fosfolipidos de nucleosidos para uso como farmacos antitumorales.
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
EP1545558A4 (en) 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
JPWO2004101593A1 (ja) 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2004311702A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
JP2007520527A (ja) 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20090074848A1 (en) * 2005-09-19 2009-03-19 Sharon Johnstone Combination formulations of cytidine analogs and platinum agents
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
UA99836C2 (en) 2007-09-26 2012-10-10 Маунт Синай Скул Оф Медсин Azacytidine analogue and using thereof

Also Published As

Publication number Publication date
WO2009042766A1 (en) 2009-04-02
MX2010003261A (es) 2010-08-18
RU2010116274A (ru) 2011-11-10
MX2010003002A (es) 2010-07-05
US8158605B2 (en) 2012-04-17
WO2009042767A1 (en) 2009-04-02
NZ583923A (en) 2012-05-25
RU2010116154A (ru) 2011-11-10
ZA201001660B (en) 2011-05-25
CN101815437A (zh) 2010-08-25
CN101877964A (zh) 2010-11-03
EP2197274A1 (en) 2010-06-23
US8399420B2 (en) 2013-03-19
RU2488591C2 (ru) 2013-07-27
BRPI0817234A2 (pt) 2014-09-30
UA99836C2 (en) 2012-10-10
NZ583824A (en) 2012-06-29
CA2700267A1 (en) 2009-04-02
JP2010540555A (ja) 2010-12-24
WO2009042766A9 (en) 2009-05-28
EP2205073A1 (en) 2010-07-14
EP2197274A4 (en) 2013-03-06
JP2010540556A (ja) 2010-12-24
AU2008304380A1 (en) 2009-04-02
KR20100102092A (ko) 2010-09-20
EP2205073A4 (en) 2013-03-06
CA2700207A1 (en) 2009-04-02
US20090209482A1 (en) 2009-08-20
UA99308C2 (ru) 2012-08-10
US20090209477A1 (en) 2009-08-20
BRPI0817269A2 (pt) 2014-10-07
KR20100072230A (ko) 2010-06-30
AU2008304381A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
IL204690A0 (en) Azacytidine analogues and uses thereof
ZA200810323B (en) Fkbp-l and uses thereof
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
IL202699A0 (en) Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EP2185692A4 (en) HCO32 AND HCO27 AND RELATED EXAMPLES
LT2064327T (lt) Dbait ir jų panaudojimas
PT2318366T (pt) Agentes de ligação a psma e suas utilizações
IL211742A0 (en) Frizzled-binding agents and uses thereof
IL194751A0 (en) Drugs and uses
GB2443336B (en) Spiruchostatin analogues and their medicinal use
ZA200903906B (en) Carboranylporphyrins and uses thereof
EP2178376A4 (en) LUPANIC TRITERPENOIDS MODIFIED IN 30-POSITION AND ITS ANALOG
GB0715428D0 (en) Compositions and uses thereof
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB0707069D0 (en) Methods and uses
HK1145418A (en) Azacytidine analogues and uses thereof
PL2227486T3 (pl) Analogi peptydowe i ich koniugaty
GB0610059D0 (en) Uses and methods
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
GB2444960B (en) Combined pseudoscope and hyperscope
GB0724878D0 (en) Peptide analogues and conjugates thereof
GB0621665D0 (en) Blogmail and podmail